What a 400-Meter Walk Reveals
An exercise-and-nutrition trial found fewer mobility-loss events in a frail older group. More falls complicated the result.
Longer lives. Better years. What the science actually says.
An exercise-and-nutrition trial found fewer mobility-loss events in a frail older group. More falls complicated the result.
Bonn researchers tracked aging marks as blood precursors became neural stem cells. The slow reset offers a way to study rejuvenation, with important limits to the headline numbers.
In middle-aged male mice, researchers traced part of a weaker cancer response to lymph nodes. The local supply of T cells available for a new response had shrunk.
Three glaucoma patients, 56 days and an early visual-field signal: ER-100 has moved beyond its first dose, but not into proof of rejuvenation.
People past 100 had expanded clones of cytotoxic CD4 T cells. The pattern suggests adaptation to persistent threats, not proof that the cells cause longevity.
RamanOmics links light-scattering chemistry to gene activity in aged mouse lung and skin. A shared lipid signal may help locate senescent cells without pretending they are one uniform target.
An analysis of 25,306 tissue slides maps nonlinear structural change across 40 human tissues. It is a research framework—not a personal age test or proof that every observed change is damage.
Ninety-two days draws attention. Keeping three mouse experiments and two human studies separate reveals what the result can actually tell us.
NIH's SenNet atlas does not prove an anti-aging therapy. It gives longevity science a harder measurement layer.
The real story is not another anti-aging pill claim. It is whether whole-body rejuvenation can survive XPRIZE's measurement machine.
The first human dosing of ER-100 does not prove age reversal. It starts the evidence clock for one of longevity's boldest ideas.
Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.